Benitec Biopharma (BNTC) Income from Continuing Operations (2019 - 2025)
Benitec Biopharma (BNTC) posted Income from Continuing Operations of 28199988.0 for Q4 2025, up 99.84% sequentially from 17378369000.0 in Q3 2025, and up 99.73% YoY from 14119103.03 in Q4 2024.
Powered by 
Analysis
Benitec Biopharma (BNTC) Income from Continuing Operations (2019 - 2025) Analysis & Trends
Benitec Biopharma has reported Income from Continuing Operations for 7 years, with the latest figure at 28199988.0 in Q4 2025.
- Quarterly Income from Continuing Operations rose 99.73% year-over-year to 28199988.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 29592465988.0 (down 64.51% YoY) and the FY2025 annual result came in at 7770149000.0, down 228.5% from the prior year.
- Income from Continuing Operations improved to 28199988.0 in Q4 2025 per BNTC's latest filing, from 17378369000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 3600000.0 in Q1 2022 and troughed at 17378369000.0 in Q3 2025.
- A 5-year average of 2383269049.4 and a median of 8263500.0 in 2022 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations slumped 78152.51% in 2024, then surged 99.73% in 2025.
- Over 5 years, Income from Continuing Operations stood at 4987000.0 in 2021, then fell by 27.07% to 6337000.0 in 2022, then tumbled by 187.36% to 18210000.0 in 2023, then sank by 57110.74% to 10418075000.0 in 2024, then soared by 99.73% to 28199988.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 28199988.0, 17378369000.0, and 10190000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Benitec Biopharma | 586.58 Mn | 586.58 Mn | - | -11.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -11.99 Mn |
| Sep 30, 2025 | -8.79 Mn |
| Jun 30, 2025 | -8.80 Mn |
| Mar 31, 2025 | -9.37 Mn |
| Dec 31, 2024 | -9.98 Mn |
| Sep 30, 2024 | -5.19 Mn |
| Jun 30, 2024 | -4.63 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Dec 31, 2023 | -6.93 Mn |
| Sep 30, 2023 | -5.88 Mn |
| Jun 30, 2023 | -4.56 Mn |
| Mar 31, 2023 | -4.35 Mn |
| Dec 31, 2022 | -5.62 Mn |
| Sep 30, 2022 | -4.59 Mn |
| Jun 30, 2022 | -4.75 Mn |
| Mar 31, 2022 | -3.47 Mn |
| Dec 31, 2021 | -4.85 Mn |
| Sep 30, 2021 | -4.82 Mn |
| Jun 30, 2021 | -3.86 Mn |
| Mar 31, 2021 | -3.80 Mn |